You are here

Guinea

Ebola pioneer, stem cell researcher honoured with Canada Gairdner Awards

CANADIAN PRESS                                                                                March 25, 2015
One of the co-discoverers of the Ebola virus and a leading Canadian stem cell researcher are among this year's winners of the prestigious Canada Gairdner Awards.

Dr. Peter Piot is the recipient of the Canada Gairdner Global Health Award, recognizing his work on the discovery of the Ebola virus in 1976 and his leadership in the global response to the HIV-AIDS epidemic.

Dr. Janet Rossant, chief of research at Toronto's Hospital for Sick Children, is the recipient of the 2015 Canada Gairdner Wightman Award, which honours a Canadian who has demonstrated outstanding leadership in medicine and medical science.

Five international scientists are also being honoured with Canada Gairdner Awards, two each from the United States and Japan and one from Switzerland....

Dr. Peter Piot won the 2015 Canada Gairdner Global Health Award in recognition of his work on the discovery of the Ebola virus in 1976 and his leadership in the global response to the HIV-AIDS epidemic. (David Azia/Associated Press)

Red complete story.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola virus not mutating as quickly as thought

SCIENCE NEWS  by Ashley Yaeger                                                      March 26, 2015

(Scroll down for full study.)

The virus causing the current Ebola epidemic in West Africa is not evolving as quickly as some scientists had suggested.

REGULAR RATE  A genetic analysis suggests that the Ebola virus, shown here in orange, is not evolving as fast as expected.

In a paper last August, researchers reported that the virus (Zaire ebolavirus) was altering its genes almost twice as fast as it had during previous Ebola outbreaks in Central Africa (SN: 9/20/14, p. 7). However, a new genetic analysis shows that the virus is mutating at roughly the same rate as in past outbreaks, researchers report online March 26 in Science. The finding suggests the virus has not become more virulent or transmissible during the West Africa outbreak.

Problem, Solution, SitRep, or ?: 

Ebola upsurge could undo progress in blink of an eye, warns expert

THE GUARDIAN by Sam Jones                           March 26, 2015

Despite the massive push to bring the number of new Ebola cases down to zero as quickly as possible, there will inevitably be “flare-ups” that could reverse the overall downward trend and prove difficult to contain, the UN’s response co-ordinator has warned.

Dr David Nabarro, the UN’s special envoy for Ebola, said the huge medical, administrative and logistical operation to fight the disease could still be set back by individuals ignoring official advice.

“There will be flare-ups, there will be disappointments; there will be people who evade quarantine – because nobody likes being told to stay put – there will be people who choose not to declare that they’ve got a relative ill, there will be people who get ill and just misdiagnose themselves,” he said....

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Dr. Gavin Macgregor-Skinner - Ebola - Health Organizations Slow to Respond

      

CLICK HERE - RECORDED VIDEO - Dr. Gavin Macgregor-Skinner

ctvnews.ca - March 23, 2015

Public health emergency expert Dr. Gavin Macgregor-Skinner discusses a new report saying faster action would have stopped the spread of Ebola.

CLICK HERE - MSF REPORT AND RELATED INFORMATION

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola Vaccine Trial Starts in Guinea

TIME MAGAZINE  by Alexandra Sifferlin                                             March 25, 2015
An efficacy trial for an Ebola vaccine launched in Guinea on Wednesday.

 

 A health worker prepares a vaccination on March 10, 2015 at a health center in Conakry during the first clinical trials of the VSV-EBOV vaccine against the Ebola virus.

The vaccine, VSV-EBOV, was developed by the Public Health Agency of Canada and has already shown positive results in smaller safety trials. NewLink Genetics and Merck are collaborating on the vaccine, and the Guinean government and World Health Organization (WHO) are leading the trial, which is taking place in Basse-Guinée, a community where many Ebola cases spread.

Country / Region Tags: 
General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Ebola Death Rates Vary Widely by Age Group

LIVE SCIENCE       by

Young children who are infected with Ebola may be more likely to die from the virus than older children or adults who are infected, according to a new study.

 In the study, researchers examined Ebola cases in children younger than 16 during the current outbreak in Guinea, Liberia and Sierra Leone, and compared them with adult cases. They found that the outbreak's death rate has been higher among younger children than among older children and adults.

The disease has killed about 90 percent of infected children under age 1, and about 80 percent of kids ages 1 to 4 who have been infected. Older children who have been infected with Ebola may have a much better chance of surviving....

"The very youngest of children — neonates  —appear to have the worst outcomes from Ebola," study co-author Dr. Robert Fowler, an associate professor of critical-care medicine at the University of Toronto, said in a statement. (Neonates, or newborns, are babies younger than 1 month.)

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Strengthening the Detection of and Early Response to Public Health Emergencies: Lessons learned from, the Ebola outbreake

PLOS MEDICINE by Mark J. Siedner, Lawrence O. Gostin, Hilarie H. Cranmer,and John D. Kraemer                        March 24, 2015

In-depth paper on lessons learned from the West Africa Ebola outbreak

Problem, Solution, SitRep, or ?: 

WHO Ebola Situation Report - 25 March 2015

WHO  WEEKLY SITUATION REPORT                                         March 25, 2015

Summary 

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

New Ebola trial vaccine 'safe': researchers

AFP                                                                                                   March 25, 2015

Paris - The latest in a string of candidate vaccines against the deadly Ebola virus was proven safe in an early trial in healthy adults in China, its developers said Wednesday.

 But while it triggered an antibody response in test subjects, further trials must be held to establish whether the drug actually protects against Ebola, they said.

Dubbed Ad5-EBOV, the vaccine is the first based on the strain of the Ebola virus behind the west African outbreak, according to a paper published in The Lancet medical journal.

Read complete story.
http://news.yahoo.com/ebola-trial-vaccine-safe-researchers-140735607.html;_ylt=AwrBJR6SwhJVFgkANl3QtDMD

Read Lancet article.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2815%2960553-0/abstract

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Study announces a durable vaccine for Ebola

MEDICAL EXPRESS                                                                                             March 25, 2015

A new study shows the durability of a novel 'disseminating' cytomegalovirus (CMV)-based Ebola virus (Zaire ebolavirus; EBOV) strategy that may eventually have the potential to reduce ebolavirus infection in wild African ape species.

These are western lowland gorillas, one of the great ape species threatened by Ebola. Credit: Copyright 2012 Chris Whittier

A cytomegalovirus (CMV)-based vaccine provides long-lasting protective immunity against Ebola virus, and has potential for development as a disseminating vaccine strategy to prevent ebolavirus infection of wild African ape populations.

The multi-institutional study is led by Dr Michael Jarvis at Plymouth University, and is published today, 25th March 2015, in Vaccine.

General Topic Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Guinea
howdy folks
Page loaded in 1.305 seconds.